Abstract
In this study, a simple, rapid, cost-effective, and sensitive reversed-phase high-performance liquid chromatographic method has been developed and validated for the analysis of moxifloxacin in plasma. The chromatographic separation was achieved on a Zorbax Eclipse XDB-C18 column (150 mm x 4.6 mm i.d.) connected to a Phenomenex C18 column (4 mm x 3.0 mm i.d.) using a mixture of acetonitrile: 15 mM citrate buffer (pH 3) (23:77, v/v) as the mobile phase with isocratic system at a flow rate of 1 mL/min. Fluorescence detection was employed with excitation at 290 nm and emission at 500 nm. Lomefloxacin was used as internal standard. Plasma samples were prepared with addition of acetonitrile only. The method was fully validated according to the International Conference on Harmonization (ICH) guidelines. The results of the validation parameters were: linearity range, 3 – 6000 ng/mL (R2 = 0.9994); mean recovery, 100.48 %; limit of quantification, 5 ng/mL; limit of detection, 1 ng/mL; and intra- and inter-day precision less than 3.2% and 5.1%, respectively. The robustness of the method was evaluated and confirmed with fractional factorial design. After validation studies, the method was applied in order to conclude the effects of pregnancy on postoperative pharmacokinetic profiles of moxifloxacin. For this aim, moxifloxacin was given to non-pregnant women (n=9) and caesarean-sectioned women (n=6) as a single intravenous dose (400 mg Avelox® infusion). Plasma samples were analyzed in order to compare pharmacokinetic profiles of pregnants and non-pregnants. Peak serum concentrations of non-pregnant and caesarean-sectioned women at the arterial port after the infusion were 4.95 ± 1.50 and 1.56 ± 0.16 μg/mL, respectively. The mean elimination half-life, volume of distribution and calculated area under the concentrationtime curve (AUC)0 – ∞ were 5.54 ± 0.73 h, 65.58 ± 6.30 L and 49.95 ± 6.30 μg h/mL for non-pregnant women and 3.50 ± 0.37 h, 215.85 ± 24.87 L and 10.53 ± 0.66 μg h/mL for caesarean-sectioned women, respectively. These results indicated that pregnancy has a significant effect on the pharmacokinetic profiles of moxifloxacin.
Keywords: Moxifloxacin, HPLC-fluorescence, validation, plasma, pharmacokinetic
Combinatorial Chemistry & High Throughput Screening
Title: Comparison of Pharmacokinetic Profiles of Moxifloxacin in Caesarean versus Non-Pregnant Sectioned Women by Fully Validated HPLC with Fluorescence Detection
Volume: 13 Issue: 6
Author(s): Emirhan Nemutlu, Sedef Kir, Hakan Eroglu, Doruk Katlan, Aykut Ozek, Ozgur Oyuncu, M. Sinan Beksac and Ozgur Ozyuncu
Affiliation:
Keywords: Moxifloxacin, HPLC-fluorescence, validation, plasma, pharmacokinetic
Abstract: In this study, a simple, rapid, cost-effective, and sensitive reversed-phase high-performance liquid chromatographic method has been developed and validated for the analysis of moxifloxacin in plasma. The chromatographic separation was achieved on a Zorbax Eclipse XDB-C18 column (150 mm x 4.6 mm i.d.) connected to a Phenomenex C18 column (4 mm x 3.0 mm i.d.) using a mixture of acetonitrile: 15 mM citrate buffer (pH 3) (23:77, v/v) as the mobile phase with isocratic system at a flow rate of 1 mL/min. Fluorescence detection was employed with excitation at 290 nm and emission at 500 nm. Lomefloxacin was used as internal standard. Plasma samples were prepared with addition of acetonitrile only. The method was fully validated according to the International Conference on Harmonization (ICH) guidelines. The results of the validation parameters were: linearity range, 3 – 6000 ng/mL (R2 = 0.9994); mean recovery, 100.48 %; limit of quantification, 5 ng/mL; limit of detection, 1 ng/mL; and intra- and inter-day precision less than 3.2% and 5.1%, respectively. The robustness of the method was evaluated and confirmed with fractional factorial design. After validation studies, the method was applied in order to conclude the effects of pregnancy on postoperative pharmacokinetic profiles of moxifloxacin. For this aim, moxifloxacin was given to non-pregnant women (n=9) and caesarean-sectioned women (n=6) as a single intravenous dose (400 mg Avelox® infusion). Plasma samples were analyzed in order to compare pharmacokinetic profiles of pregnants and non-pregnants. Peak serum concentrations of non-pregnant and caesarean-sectioned women at the arterial port after the infusion were 4.95 ± 1.50 and 1.56 ± 0.16 μg/mL, respectively. The mean elimination half-life, volume of distribution and calculated area under the concentrationtime curve (AUC)0 – ∞ were 5.54 ± 0.73 h, 65.58 ± 6.30 L and 49.95 ± 6.30 μg h/mL for non-pregnant women and 3.50 ± 0.37 h, 215.85 ± 24.87 L and 10.53 ± 0.66 μg h/mL for caesarean-sectioned women, respectively. These results indicated that pregnancy has a significant effect on the pharmacokinetic profiles of moxifloxacin.
Export Options
About this article
Cite this article as:
Nemutlu Emirhan, Kir Sedef, Eroglu Hakan, Katlan Doruk, Ozek Aykut, Oyuncu Ozgur, Sinan Beksac M. and Ozyuncu Ozgur, Comparison of Pharmacokinetic Profiles of Moxifloxacin in Caesarean versus Non-Pregnant Sectioned Women by Fully Validated HPLC with Fluorescence Detection, Combinatorial Chemistry & High Throughput Screening 2010; 13 (6) . https://dx.doi.org/10.2174/138620710791516003
DOI https://dx.doi.org/10.2174/138620710791516003 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Computational Overview of Mycobacterial Thymidine Monophosphate Kinase
Current Pharmaceutical Design The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design The Asymmetric Pictet – Spengler Reaction
Current Organic Synthesis In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone
Drug Metabolism Letters Subject Index to Volume 1
Current Pharmacogenomics Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method
Letters in Drug Design & Discovery New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Preventive Strategies for Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sequence-Structure Similarity: Do Sequentially Identical Peptide Fragments have Similar Three-Dimensional Structures?
Current Bioinformatics Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design Two Neglected Multicomponent Reactions: Asinger and Groebke Reaction for Constructing Thiazolines and Imidazolines
Current Organic Synthesis Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Prospective Observation for Seven-Year's Highly Active Antiretroviral Therapy in Chinese HIV-1 Infected Patients
Current HIV Research Medicinal Plants for the Treatment of Asthma: A Traditional Persian Medicine Perspective
Current Pharmaceutical Design Effect of Vitamin D Supplementation in Type 2 Diabetes Patients with Tuberculosis: A Systematic Review
Current Diabetes Reviews Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry 3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors
Current Pharmaceutical Design